Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
Neurobiol Dis. 2012 Apr;46(1):157-64. doi: 10.1016/j.nbd.2012.01.001. Epub 2012 Jan 11.
We investigated axonal plasticity in the bilateral motor cortices and the long term therapeutic effect of Niaspan on axonal remodeling after stroke in type-1 diabetic (T1DM) rats.
T1DM was induced in young adult male Wistar rats via injection of streptozotocin. T1DM rats were subjected to 2h transient middle cerebral artery occlusion (MCAo) and were treated with 40 mg/kg Niaspan or saline starting 24 h after MCAo and daily for 28 days. Anterograde tracing using biotinylated dextran amine (BDA) injected into the contralateral motor cortex was performed to assess axonal sprouting in the ipsilateral motor cortex area. Functional outcome, SMI-31 (a pan-axonal microfilament marker), Bielschowsky silver and synaptophysin expression were measured. In vitro studies using primary cortical neuron (PCN) cultures and in vivo BDA injection into the brain to anterogradely label axons and terminals were employed.
Niaspan treatment of stroke in T1DM-MCAo rats significantly improved functional outcome after stroke and increased SMI-31, Bielschowsky silver and synaptophysin expression in the ischemic brain compared to saline treated T1DM-MCAo rats (p<0.05). Using BDA to anterograde label axons and terminals, Niaspan treatment significantly increased axonal density in ipsilateral motor cortex in T1DM-MCAo rats (p<0.05, n=7/group). Niacin treatment of PCN significantly increased Ang1 expression under high glucose condition. Niacin and Ang1 significantly increased neurite outgrowth, and anti-Ang1 antibody marginally attenuated Niacin induced neurite outgrowth (p=0.06, n=6/group) in cultured PCN under high glucose condition.
Niaspan treatment increased ischemic brain Ang1 expression and promoted axonal remodeling in the ischemic brain as well as improved functional outcome after stroke. Ang1 may partially contribute to Niaspan-induced axonal remodeling after stroke in T1DM-rats.
我们研究了 1 型糖尿病(T1DM)大鼠大脑皮质双侧皮质区轴突重塑的轴突可塑性,以及尼可司汀对卒中后轴突重塑的长期治疗效果。
通过链脲佐菌素注射诱导年轻成年雄性 Wistar 大鼠发生 T1DM。T1DM 大鼠接受 2 小时短暂性大脑中动脉闭塞(MCAo),并于 MCAo 后 24 小时开始每日给予 40mg/kg 尼可司汀或生理盐水治疗,共 28 天。通过将生物素化葡聚糖胺(BDA)注射到对侧运动皮质来进行顺行示踪,以评估同侧运动皮质区的轴突发芽情况。通过测量功能结果、SMI-31(一种泛轴突微丝标记物)、Bielschowsky 银染和突触素表达来评估。采用原代皮质神经元(PCN)培养和脑内 BDA 注射进行顺行标记轴突和末梢的体外研究。
与生理盐水治疗的 T1DM-MCAo 大鼠相比,尼可司汀治疗 T1DM-MCAo 大鼠卒中后显著改善了卒中后的功能结果,并增加了缺血大脑中的 SMI-31、Bielschowsky 银染和突触素表达(p<0.05)。通过 BDA 进行顺行标记轴突和末梢,尼可司汀治疗显著增加了 T1DM-MCAo 大鼠对侧皮质运动区的轴突密度(p<0.05,每组 n=7)。高葡萄糖条件下,烟酰胺治疗显著增加了 Ang1 的表达。高葡萄糖条件下,烟酰胺和 Ang1 显著增加了神经突的生长,抗 Ang1 抗体则轻微减弱了烟酰胺诱导的神经突生长(p=0.06,每组 n=6)。
尼可司汀治疗增加了缺血大脑的 Ang1 表达,促进了缺血大脑的轴突重塑,并改善了卒中后的功能结果。Ang1 可能部分有助于 T1DM 大鼠卒中后尼可司汀诱导的轴突重塑。